Cancer is a heterogeneous disease, meaning every tumour may addict to distinct oncogenic mechanisms and therefore need personalised treatment. This complexity could arise from genomic alterations (e.g. mutations), microenvironment changes (e.g. immune cells) and their interactions. Nevertheless, current therapeutic development mainly focuses on one of these alterations, resulting poor response in many cases.
Dr Haonan Lu was previously trained in bioinformatics and cell biology at Imperial College London. He is particularly interested in developing imaging-based methods to describe cancer phenotypes, as well as discovering novel therapeutic targets through functional genomics approach.
et al., 2023, Radiomics and artificial intelligence for precision medicine in lung cancer treatment., Semin Cancer Biol, Vol:93, Pages:97-113
et al., 2023, Tumour and local lymphoid tissue interaction determines prognosis in high grade serous ovarian cancer, Cell Reports Medicine, Vol:4, ISSN:2666-3791, Pages:1-24
et al., 2023, A novel radiogenomics biomarker for predicting treatment response and pneumotoxicity from programmed cell death protein or ligand-1 inhibition immunotherapy in NSCLC, Journal of Thoracic Oncology, Vol:18, ISSN:1556-0864, Pages:718-730